Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma
NCT02575261Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial in malignant glioma (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Effectiveness of CAR-T cell immunotherapy at 24 weeks. Planned start Sep 2015; status: withdrawn.
02
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02575261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02575261.